Potential Use of Sofosbuvir in the Prophylaxis for Rabies
暂无分享,去创建一个
[1] P. German,et al. The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C Infection , 2018, Drug Metabolism and Disposition.
[2] B. Canard,et al. Substrate selectivity of Dengue and Zika virus NS5 polymerase towards 2′‐modified nucleotide analogues , 2017, Antiviral research.
[3] M. Sofia. Enter Sofosbuvir: The Path to Curing HCV , 2016, Cell.
[4] P. Gong,et al. Structural basis of viral RNA-dependent RNA polymerase catalysis and translocation , 2016, Proceedings of the National Academy of Sciences.
[5] S. Hill,et al. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis , 2016, PLoS medicine.
[6] A. Nishizono,et al. Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis , 2015, The Journal of infectious diseases.
[7] F. Zeiler,et al. Critical Appraisal of the Milwaukee Protocol for Rabies: This Failed Approach Should Be Abandoned , 2015, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[8] Helen Yu,et al. Role of Mitochondrial RNA Polymerase in the Toxicity of Nucleotide Inhibitors of Hepatitis C Virus , 2015, Antimicrobial Agents and Chemotherapy.
[9] Antonio Lazcano,et al. Structural Analysis of Monomeric RNA-Dependent Polymerases: Evolutionary and Therapeutic Implications , 2015, PloS one.
[10] Bo Liang,et al. Structure of the L Protein of Vesicular Stomatitis Virus from Electron Cryomicroscopy , 2015, Cell.
[11] H. Wilde,et al. The "Milwaukee protocol" for treatment of human rabies is no longer valid. , 2015, The Pediatric infectious disease journal.
[12] Louise Taylor,et al. Correction: Estimating the Global Burden of Endemic Canine Rabies , 2015, PLoS neglected tropical diseases.
[13] A. Mathias,et al. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir , 2015, Clinical Pharmacokinetics.
[14] Xiaorong Yang,et al. Targeting structural dynamics of the RNA-dependent RNA polymerase for anti-viral strategies. , 2014, Current opinion in virology.
[15] A. T. Velthuis. Common and unique features of viral RNA-dependent polymerases , 2014, Cellular and Molecular Life Sciences.
[16] S. Whelan,et al. Sensitivity of the Polymerase of Vesicular Stomatitis Virus to 2′ Substitutions in the Template and Nucleotide Triphosphate during Initiation and Elongation* , 2014, The Journal of Biological Chemistry.
[17] G. Keating,et al. Sofosbuvir: First Global Approval , 2014, Drugs.
[18] N. Ford,et al. Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] E. Kopel,et al. Inadequate Antibody Response to Rabies Vaccine in Immunocompromised Patient , 2012, Emerging infectious diseases.
[20] C. Hatz,et al. Rabies: relevance, prevention, and management in travel medicine. , 2012, Infectious disease clinics of North America.
[21] C. V. van Dolleweerd,et al. Passive immunity in the prevention of rabies. , 2012, The Lancet. Infectious diseases.
[22] R. Ruigrok,et al. Structural insights into the rhabdovirus transcription/replication complex. , 2011, Virus research.
[23] P. Walker,et al. Overview, Prevention, and Treatment of Rabies , 2009, Pharmacotherapy.
[24] H. Wilde,et al. Survival after treatment of rabies. , 2005, The New England journal of medicine.
[25] C. Rupprecht,et al. Survival after treatment of rabies with induction of coma. , 2005, The New England journal of medicine.
[26] C. Rupprecht,et al. Prophylaxis against rabies , 2004 .
[27] Katherine J. Johnson,et al. The global availability of rabies immune globulin and rabies vaccine in clinics providing direct care to travelers. , 2013, Journal of travel medicine.
[28] WHO Expert Consultation on Rabies. Second report. , 2013, World Health Organization technical report series.